Paul Klas, MD
Dermatology · Tualatin, ORNPI 1508999152
Payments from drug & device makers
What this record shows
This record is dominated by education: $539 of the $813 with a category attached, or 66.3%. Johnson & Johnson accounts for 68.2% of it on its own, with 6 other manufacturers making up the rest. That places this record below the midpoint for dermatology clinicians in OR, where the typical reported total is $1,330.
Across 20 payments — averaging $40.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$554
- E.r. Squibb & Sons, L.L.C.$81
- Novartis$69
- Amgen$55
- KCI USA, Inc.$24
- AbbVie$16
- plus $14 from 1 others
Across 6 payments — averaging $13,047 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$78K
What the payments were for
- Food & beverage$27434%
- Education$53966%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $554 |
| E.r. Squibb & Sons, L.L.C. | 3 | $81 |
| Novartis | 4 | $69 |
| Amgen | 3 | $55 |
| KCI USA, Inc. | 1 | $24 |
| AbbVie | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$813 in reported general payments places this provider in the 40th percentile of 175 dermatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $85,351 |
| Doxycycline Monohydrate | 50 | $2,375 |
| Betamethasone Dipropionate | 28 | $1,109 |
| Ketoconazole | 43 | $1,069 |
| Mometasone Furoate | 57 | $974 |
| Metronidazole | 15 | $894 |
| Triamcinolone Acetonide | 99 | $878 |
| ValacyclovirValacyclovir Hcl | 34 | $831 |
| Clobetasol Propionate | 24 | $697 |
| Minocycline Hcl | 12 | $604 |
| Fluocinonide | 14 | $478 |
| Diazepam | 13 | $270 |
| Terbinafine Hcl | 13 | $220 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $191 |
| Hydrocortisone | 17 | $148 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Tualatin
- Andrew BlauveltPortland$1.8M
- Benjamin EhstPortland$1.5M
- Jason HawkesPortland$1.5M
- Eric SimpsonPortland$1.4M
- Collin BlattnerThe Dalles$409K
- Alex Ortega LoayzaPortland$122K
- Omar QutubPortland$107K
- Paul HaunPortland$85K
- Erin GrinichHillsboro$72K
- Kathryn SchwarzenbergerPortland$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.